Mukkamala, Ramakrishna
Kohl, Benjamin A.
Mahajan, Aman
Article History
Received: 28 February 2021
Accepted: 17 June 2021
First Online: 10 July 2021
Declarations
:
: This study is a secondary analysis of existing, de-identified patient data. The Institutional Review Board of Michigan State University (East Lansing, USA) declared that this secondary analysis did not constitute human subjects research (MSU Study ID: STUDY00002367).
: Not applicable.
: R. M. is Co-Founder, Chief Technology Officer, and Board Member of Retia Medical (Valhalla, NY, USA) and has equity and a paid consulting agreement with the company. B. A. K. is an unpaid member of the Clinical Advisory Board of Retia Medical. A. M. declares no conflicts of interest.